<b>Gapping up</b><br/><b>In reaction to strong earnings/guidance: </b>HOFT +6.8%, GBX +5.6%, MY +4.8%, ISCA +2.9%, .<br/><br/><b>M&A news: </b>INFA +5.2% (confirms agreement to be acquired by the Permira Funds and Canada Pension Plan Investment Board; transaction valued at approx $5.3 billion or $48.75 per share), FDX +4.5% (FedEx and TNT Express (TNTEY) agree on recommended all-cash public offer for all TNT Express shares for $4.8 billion), .<br/><br/><b>Select oil/gas related names showing strength: </b>SSL +3.6%, STO +1.6%, BP +1.2%, RDS.A +1.1%, SDRL +0.8%<br/><br/><b>Other news:</b> VBIV +20% (announced collaboration with Sanofi Pasteur (SNY) to to apply VBI's Lipid Particle Vaccine formulation technology to further the development of Sanofi Pasteur vaccine candidate), ONVO +13.5% (disclosed it entered into a research collaboration agreement with L'Oreal (LRLCY) USA products), BLDP +10.2% (announced that the world's first hydrogen fuel cell powered fixed rail electric tram was successfully demonstrated; production and testing facility of CSR Qingdao Sifang Company), CLVS +8.9% (received breakthrough therapy designation for Rucaparib for monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors), OCN +8% (co disclosed it amended its agreement with Home Loan Servicing Solutions (HLSS); New Residential Investment (NRZ) agreed to a multi-year extension of the servicing contracts with OCN), LSG +7.9% (announces record quarterly production in the first quarter of 2015), ARNA +7.8% (Arena Pharm and Eisai (ESALY) receives additional patent for Belviq), QEPM +7.2% (to be acquired in full by Tesoro Logistics LP (TLLP); consideration is valued at $17.09 per QEPM common unit), CYTX +5.3% (announces the European Commission has designated Cytori's ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma), AXTA +3.5% (announces that an affiliate of Berkshire Hathaway (BRK.B) has entered into a definitive stock purchase agreement with certain affiliates of The Carlyle Group (CG) for the purchase of a total of 20 mln of Axalta's common stock at $28.00 per share), SHPG +2.7% (announces clear regulatory path forward for SHP465, an investigational treatment for adults with ADHD), CLDX +0.9% (announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology)<br/><br/><b>Analyst comments:</b> BIND +10.2% (initiated with an Outperform at Oppenheimer), CLDN +4.6% (initiated with a Buy at H.C. Wainwright), RYAAY +4% (upgraded to Overweight from Neutral at JP Morgan; also reported Mar traffic stats), SPLK +3.8% (upgraded to Overweight from Neutral at Piper Jaffray ), PAY +2.5% (upgraded to Buy from Hold at Stifel), DWRE +2.2% (added to Conviction Buy List at Goldman), CCL +1.1% (upgraded to Outperform from Market Perform at Wells Fargo ), TOT +1.1% ( upgraded to Outperform from Sector Perform at RBC Capital Mkts), JPM +0.8% (upgraded to Outperform from Mkt Perform at Bernstein), RL +0.7% (upgraded to Buy from Outperform at Credit Agricole)<br/><br/><b>Gapping down</b><br/><b>In reaction to disappointing earnings/guidance: </b>SHLM -2.9%, ABGB -2.8%, AZZ -2.1%<br/><br/><b>Select metals/mining stocks trading lower:</b> AG -3.5%, SSRI -2.8%, GFI -1.6%, ABX -1.3%<br/><br/><b>Other news:</b> OCUL -33.3% (reported topline clinical data for its second Phase 3 clinical trial evaluating OTX-DP), HELI -12.8% announced tender offer to purchase up to $80 mln of its outstanding 9.375% senior notes due 2021), MX -8.3% (announced it received an expected notice of noncompliance with NYSE continued listing requirements due to failure to file Form 10-K), GEL -5.9% (announces pricing of 4 mln unit public offering at $44.42/unit), VLTC -5% (modest pullback after yday's advance), FCH -4% (announced that it is commencing a public offering of 14.5 mln shares of its common stock; reported Q1 RevPAR grew 13.1% yoy to $132.9), WBAI -3.6% (issued clarifiaction on announcement regarding online lottery sales in China; believes approval to provide online lottery sales in China is valid and has not been revoked or amended), DYAX -2.8% (announced proposed 7 mln share public offering of common stock), NBG -2.3% (cont uncertainty surrounding Greece), NRZ -2.1% (announced public offering of 40 mln shares of common stock; ~28.3 mln shares being offered by Home Loan Servicing Solutions (HLSS), remainder being sold by the company), GM -2.1% (Government of Canada announced the divestiture of its remaining shares in GM), HPP -1.6% (announces the pricing of an underwritten public offering of 5.25 mln shares of its common stock by selling stockholders), VIAB -1.6% (details strategic realignment), CERU -1.5% (priced its underwritten public offering of 5.84 mln shares of its common stock at a public offering price of $6.00 per share)<br/><br/><b>Analyst comments:</b> UBNT -2.9% (downgraded to Underperform at BofA/Merrill), AXP -1.3% (downgraded to Underperform from Perform at Oppenheimer), TM -0.9% (downgraded to Neutral from Buy at UBS)<br/><br/><b>Allikas</b>: Briefing.com